Related references
Note: Only part of the references are listed.Comparative Study of the Anti-leukemic Effects of Imatinib Mesylate, Glivec™ Tablet and Its Generic Formulation, OHK9511
Masako Yokoo et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Clinical efficacy of generic imatinib
Mario L. de Lemos et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Generic imatinib: the real-deal or just a deal?
Vikram Mathews
LEUKEMIA & LYMPHOMA (2014)
Tyrosine kinase inhibitors becoming generic drugs risks and chances from a regulatory perspective
Niels Eckstein et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008
Purvish Parikh
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2013)
Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase
Mervat Mattar
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report
Zoubir Chouffai
CASE REPORTS IN ONCOLOGY (2010)
Bioequivalence of Two Film-Coated Tablets of Imatinib Mesylate 400 mg: A Randomized, Open-Label, Single-Dose, Fasting, Two-Period, Two-Sequence Crossover Comparison in Healthy Male South American Volunteers
Susana Parrillo-Campiglia et al.
CLINICAL THERAPEUTICS (2009)
Share Paper
